ClinicalTrials.gg
TerminatedNCT05497284Updated Jan 13, 2026Results posted

To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF

A Phase 2 interventional study of LTP001 and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Novartis Pharmaceuticals. Terminated at 15 sites in 7 countries. Open to participants aged 40 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
40 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Idiopathic Pulmonary Fibrosis with a site in Argentina — 5 open to participants now, 11 under way, 4 of them phase 3. Idiopathic Pulmonary Fibrosis · Argentina.

Enrollment
29th of 29
46 · median 340
Started
2022
with 5 others
Phase 2
17 of 29
3 open now
Registered
16th of 29
by date

Among the 29 studies in Idiopathic Pulmonary Fibrosis with a site in Argentina, this one is the 29th largest by enrollment, is one of 6 that started in 2022, is one of 17 in phase 2, and was the 16th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

5 of the 29 studies in Idiopathic Pulmonary Fibrosis with a site in Argentina are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Idiopathic Pulmonary Fibrosis with a site in Argentina, or all of them as a file.
02

Study summary

A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis

Read the detailed description

This was a randomized, placebo-controlled, participant- and investigator-blinded platform study in participants with idiopathic pulmonary fibrosis. Participants underwent a screening period of 42 days, a treatment period of 26 weeks and a post-treatment safety follow-up period of 30 days. This study was designed to safely allow rapid and efficient screening of potentially efficacious investigational products in participants with IPF. The study was terminated for strategic reasons and no additional cohorts were created.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • Idiopathic pulmonary fibrosis
  • FVC
  • DLCO
  • 6-minute walk test
  • patient reported outcome
  • HRCT
04

Who can participate

Ages eligible
40 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants at least 40 years of age
  • IPF diagnosed based on ATS/ERS/JRS/ALAT IPF 2018 modified guidelines
  • FVC ≥45% predicted
  • DLCO, corrected for , ≥25% predicted (inclusive)
  • Unlikely to undergo lung transplantation during this trial in the opinion of the investigator
  • If a participant is taking nintedanib or pirfenidone, they must be on a stable regimen for at least 8 weeks prior to randomization

Exclusion criteria

Exclusion Criteria:

  • Airway obstruction (i.e. prebronchodilator / FVC \< 0.7) or evidence of a bronchodilator response at screening
  • Emphysema >20% on screening HRCT
  • Fibrosis \<10% on screening HRCT
  • Clinical diagnosis of any connective tissue disease
  • Clinically diagnosed acute exacerbation of IPF (AE-IPF) or other significant clinical worsening within 3 months of randomization

Additional protocol-defined inclusion / exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    LTP001

    LTP001 orally once daily in the morning for approximately 26 weeks.

    Drug: LTP001 · Drug: Standard of Care (SoC)

  • Experimental
    Placebo

    Placebo orally once daily in the morning for approximately 26 weeks.

    Drug: Placebo · Drug: Standard of Care (SoC)

Interventions

  • DrugLTP001

    LTP001 administered once daily in the morning

  • DrugPlacebo

    Placebo to LTP001 administered once daily in the morning

  • DrugStandard of Care (SoC)

    nintedanib, pirfenidone, or neither

06

What researchers measure

Primary outcomes

  1. Change From Baseline to End of Treatment Epoch in Forced Vital Capacity (FVC) Expressed in Percent Predicted

    Forced Vital Capacity (FVC) is the total amount of air exhaled during the Forced expiratory volume (FEV) test measured through spirometry testing. FEV measures how much air a person can exhale during a forced breath. It is expressed as percent predicted, defined as FVC of the participant divided by the average FVC in the population for any person of similar age, sex, and body composition multiplied by 100. A positive change from baseline is considered a favorable outcome.

    Time frame: Baseline, up to approximately 26 weeks

Secondary outcomes

  1. Change From Baseline to End of Treatment Epoch in FVC

    Forced Vital Capacity (FVC) is the total amount of air exhaled during the Forced expiratory volume (FEV) test measured through spirometry testing. FEV measures how much air a person can exhale during a forced breath. A positive change from baseline is considered a favorable outcome.

    Time frame: Baseline, up to approximately 26 weeks

  2. Progression-free Survival (PFS)

    PFS is defined as the time from the date of randomization to the date of the any of the following events: Absolute reduction from baseline of ≥10% predicted in FVC, Nonelective hospitalization for respiratory events, Lung Transplant, Death. PFS was analyzed based on Kaplan-Meier estimates.

    Time frame: Baseline, up to approximately 26 weeks

  3. Number of Participants With Absolute Decline of ≥10% Predicted in FVC

    Binary output of absolute decline of ≥ 10% predicted in FVC (Yes/No) at the end of treatment epoch.

    Time frame: Baseline, up to approximately 26 weeks

  4. Change From Baseline to the End of Treatment Epoch in Diffusion Capacity of Lung for Carbon Monoxide (DLCO)

    Diffusing capacity of the lungs for carbon monoxide (DLCO) is a measurement to assess the ability of the lungs to transfer gas from inspired air to the bloodstream. Inhaled carbon monoxide (CO) is used for this test due to its high affinity for hemoglobin. During a ten-second breath-hold, DLCO measures uptake of CO per time per CO pressure.

    Time frame: Baseline, up to approximately 26 weeks

  5. Change From Baseline to the End of Treatment Epoch in 6-minute Walk Distance (6MWD)

    The 6MWD test is self-paced, with standardized instructions and encouragement being given as participants walk as far as possible over 6 minutes through a flat corridor. The final distance is recorded in meters. A positive change from baseline in 6MWD is considered a favourable outcome.

    Time frame: Baseline, up to approximately 26 weeks

  6. Change From Baseline to the End of Treatment Epoch in Total Score From the K-BILD Questionnaire

    The King's Brief Interstitial Lung Disease (K-BILD) is a 15-item HRQOL questionnaire that range from 0 to 100. Higher scores indicate better health-related quality of life, with 100 representing the best possible health status. A positive change from baseline in K-BILD questionnaire is considered a favourable outcome.

    Time frame: Baseline, up to approximately 26 weeks

  7. Change From Baseline to the End of Treatment Epoch in Scores From Leicester Cough Questionnaire

    The Leicester Cough Questionnaire (LCQ) is a 19-item validated patient-report questionnaire that measures the impact of cough on quality of life. It takes about 5 minutes to complete and results in three domain scores (Social, Psychological, and Physical), and one Total score. Domain scores are averages of the questions that make up each domain. Minimum and maximum domain scores are 1 and 7, respectively. The domain scores are summed to determine the Total score, which can range from 3 to 21. A higher score means less impact on quality of life. A positive LCQ change score indicates an improvement.

    Time frame: Baseline, up to approximately 26 weeks

  8. Change From Baseline to the End of Treatment Epoch in Scores From the the R-Scale for IPF Questionnaire

    The Raghu-Scale for Pulmonary Fibrosis (R-Scale for PF) is a questionnaire designed to assess the impact of lung disease on quality of life. The R-Scale-PF uses a numerical rating scale to assess the severity of five symptoms: cough, shortness of breath, fatigue, depressed mood, and overall sense of wellbeing, over the past two weeks. Each item is scored from 0 to 10, with lower scores indicating better health-related quality of life. The total R-Scale-PF score ranges from 0 to 50. A decrease from baseline in R-Scale for PF is considered a favourable outcome.

    Time frame: Baseline, up to approximately 26 weeks

  9. Change From Baseline to the End of Treatment Epoch in Total Score From the Living With IPF Questionnaire

    Living with idiopathic pulmonary fibrosis (L-IPF) is a tool that assesses symptoms and impacts of IPF. The Symptoms Module consists of 20 questions to assess symptoms experienced from IPF over the last 24 hours. The Impacts Module consists of 20 questions on how IPF affects quality of life over the last 7 days. The total score ranging from 0 to 100, with higher scores indicating greater symptom severity. A positive change from baseline in L-IPF is considered a favourable outcome.

    Time frame: Baseline, up to approximately 26 weeks

07

Results

Posted Sep 18, 2025

Participant flow

Participants took part at 15 investigative sites in 7 countries.

Participant flow — Overall Study
MilestoneLTP001 6mgPlacebo
Started2323
Completed1517
Not completed86
Withdrew: Adverse event10
Withdrew: Physician decision01
Withdrew: Study terminated by sponsor74
Withdrew: Subject decision01

Outcome measures

PrimaryChange From Baseline to End of Treatment Epoch in Forced Vital Capacity (FVC) Expressed in Percent Predicted

Forced Vital Capacity (FVC) is the total amount of air exhaled during the Forced expiratory volume (FEV) test measured through spirometry testing. FEV measures how much air a person can exhale during a forced breath. It is expressed as percent predicted, defined as FVC of the participant divided by the average FVC in the population for any person of similar age, sex, and body composition multiplied by 100. A positive change from baseline is considered a favorable outcome.

Time frame:
Baseline, up to approximately 26 weeks
Reported as:
Mean · Percentage of predicted FVC
Change From Baseline to End of Treatment Epoch in Forced Vital Capacity (FVC) Expressed in Percent Predicted
Percentage of predicted FVCLTP001 6mgPlacebo
Change From Baseline to End of Treatment Epoch in Forced Vital Capacity (FVC) Expressed in Percent Predicted-3.1 ± 4.80-1.1 ± 5.31
Statistical analysis
  • LTP001 6mg vs Placebo · Baysesian random slope model · Slope: -2.6 · 80% CI -6.9 to 1.3Bayesian random slope model to assess the difference in reduction rate (slope) in years between the treatment group and placebo group.
SecondaryChange From Baseline to End of Treatment Epoch in FVC

Forced Vital Capacity (FVC) is the total amount of air exhaled during the Forced expiratory volume (FEV) test measured through spirometry testing. FEV measures how much air a person can exhale during a forced breath. A positive change from baseline is considered a favorable outcome.

Time frame:
Baseline, up to approximately 26 weeks
Reported as:
Mean · mL
Change From Baseline to End of Treatment Epoch in FVC
mLLTP001 6mgPlacebo
Change From Baseline to End of Treatment Epoch in FVC-120.0 ± 181.56-45.5 ± 176.25
SecondaryProgression-free Survival (PFS)

PFS is defined as the time from the date of randomization to the date of the any of the following events: Absolute reduction from baseline of ≥10% predicted in FVC, Nonelective hospitalization for respiratory events, Lung Transplant, Death. PFS was analyzed based on Kaplan-Meier estimates.

Time frame:
Baseline, up to approximately 26 weeks
Reported as:
Median · Days
Progression-free Survival (PFS)
DaysLTP001 6mgPlacebo
Progression-free Survival (PFS)185.0 (180.0 to NA)185.0 (183.0 to NA)
SecondaryNumber of Participants With Absolute Decline of ≥10% Predicted in FVC

Binary output of absolute decline of ≥ 10% predicted in FVC (Yes/No) at the end of treatment epoch.

Time frame:
Baseline, up to approximately 26 weeks
Reported as:
Count of participants · Participants
Number of Participants With Absolute Decline of ≥10% Predicted in FVC
ParticipantsLTP001 6mgPlacebo
Number of Participants With Absolute Decline of ≥10% Predicted in FVC65
SecondaryChange From Baseline to the End of Treatment Epoch in Diffusion Capacity of Lung for Carbon Monoxide (DLCO)

Diffusing capacity of the lungs for carbon monoxide (DLCO) is a measurement to assess the ability of the lungs to transfer gas from inspired air to the bloodstream. Inhaled carbon monoxide (CO) is used for this test due to its high affinity for hemoglobin. During a ten-second breath-hold, DLCO measures uptake of CO per time per CO pressure.

Time frame:
Baseline, up to approximately 26 weeks
Reported as:
Mean · mL/min/mmHg
Change From Baseline to the End of Treatment Epoch in Diffusion Capacity of Lung for Carbon Monoxide (DLCO)
mL/min/mmHgLTP001 6mgPlacebo
Change From Baseline to the End of Treatment Epoch in Diffusion Capacity of Lung for Carbon Monoxide (DLCO)-0.167 ± 1.5568-0.334 ± 2.3838
SecondaryChange From Baseline to the End of Treatment Epoch in 6-minute Walk Distance (6MWD)

The 6MWD test is self-paced, with standardized instructions and encouragement being given as participants walk as far as possible over 6 minutes through a flat corridor. The final distance is recorded in meters. A positive change from baseline in 6MWD is considered a favourable outcome.

Time frame:
Baseline, up to approximately 26 weeks
Reported as:
Mean · meters
Change From Baseline to the End of Treatment Epoch in 6-minute Walk Distance (6MWD)
metersLTP001 6mgPlacebo
Change From Baseline to the End of Treatment Epoch in 6-minute Walk Distance (6MWD)9.2 ± 63.064.7 ± 56.66
SecondaryChange From Baseline to the End of Treatment Epoch in Total Score From the K-BILD Questionnaire

The King's Brief Interstitial Lung Disease (K-BILD) is a 15-item HRQOL questionnaire that range from 0 to 100. Higher scores indicate better health-related quality of life, with 100 representing the best possible health status. A positive change from baseline in K-BILD questionnaire is considered a favourable outcome.

Time frame:
Baseline, up to approximately 26 weeks
Reported as:
Mean · score on scale
Change From Baseline to the End of Treatment Epoch in Total Score From the K-BILD Questionnaire
score on scaleLTP001 6mgPlacebo
Change From Baseline to the End of Treatment Epoch in Total Score From the K-BILD Questionnaire17.17 ± 174.0097.94 ± 136.768
SecondaryChange From Baseline to the End of Treatment Epoch in Scores From Leicester Cough Questionnaire

The Leicester Cough Questionnaire (LCQ) is a 19-item validated patient-report questionnaire that measures the impact of cough on quality of life. It takes about 5 minutes to complete and results in three domain scores (Social, Psychological, and Physical), and one Total score. Domain scores are averages of the questions that make up each domain. Minimum and maximum domain scores are 1 and 7, respectively. The domain scores are summed to determine the Total score, which can range from 3 to 21. A higher score means less impact on quality of life. A positive LCQ change score indicates an improvement.

Time frame:
Baseline, up to approximately 26 weeks
Reported as:
Mean · score on scale
Change From Baseline to the End of Treatment Epoch in Scores From Leicester Cough Questionnaire
score on scaleLTP001 6mgPlacebo
Change From Baseline to the End of Treatment Epoch in Scores From Leicester Cough Questionnaire-3.9 ± 14.232.7 ± 18.35
SecondaryChange From Baseline to the End of Treatment Epoch in Scores From the the R-Scale for IPF Questionnaire

The Raghu-Scale for Pulmonary Fibrosis (R-Scale for PF) is a questionnaire designed to assess the impact of lung disease on quality of life. The R-Scale-PF uses a numerical rating scale to assess the severity of five symptoms: cough, shortness of breath, fatigue, depressed mood, and overall sense of wellbeing, over the past two weeks. Each item is scored from 0 to 10, with lower scores indicating better health-related quality of life. The total R-Scale-PF score ranges from 0 to 50. A decrease from baseline in R-Scale for PF is considered a favourable outcome.

Time frame:
Baseline, up to approximately 26 weeks
Reported as:
Mean · score on scale
Change From Baseline to the End of Treatment Epoch in Scores From the the R-Scale for IPF Questionnaire
score on scaleLTP001 6mgPlacebo
Change From Baseline to the End of Treatment Epoch in Scores From the the R-Scale for IPF Questionnaire1.53 ± 5.784-0.93 ± 6.020
SecondaryChange From Baseline to the End of Treatment Epoch in Total Score From the Living With IPF Questionnaire

Living with idiopathic pulmonary fibrosis (L-IPF) is a tool that assesses symptoms and impacts of IPF. The Symptoms Module consists of 20 questions to assess symptoms experienced from IPF over the last 24 hours. The Impacts Module consists of 20 questions on how IPF affects quality of life over the last 7 days. The total score ranging from 0 to 100, with higher scores indicating greater symptom severity. A positive change from baseline in L-IPF is considered a favourable outcome.

Time frame:
Baseline, up to approximately 26 weeks
Reported as:
Mean · score on scale
Change From Baseline to the End of Treatment Epoch in Total Score From the Living With IPF Questionnaire
score on scaleLTP001 6mgPlacebo
Change From Baseline to the End of Treatment Epoch in Total Score From the Living With IPF Questionnaire7.15 ± 14.392-4.48 ± 11.067

Adverse events

Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus follow up period, up to a maximum duration of approximately 30 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LTP001 6 mg1/23 (4.3%)2/23 (8.7%)14/23 (60.9%)
Placebo0/23 (0%)1/23 (4.3%)7/23 (30.4%)
Total1/46 (2.2%)3/46 (6.5%)21/46 (45.7%)
Most frequent serious events
Most frequent serious events
EventLTP001 6 mgPlaceboTotal
Herpes zosterInfections and infestations1/230/231/46
InfectionInfections and infestations1/230/231/46
Bladder disorderRenal and urinary disorders1/230/231/46
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders1/231/232/46
Most frequent other events
Most frequent other events
EventLTP001 6 mgPlaceboTotal
DiarrhoeaGastrointestinal disorders5/231/236/46
ArthralgiaMusculoskeletal and connective tissue disorders3/231/234/46
BronchitisInfections and infestations2/230/232/46
PneumoniaInfections and infestations0/232/232/46
Urinary tract infectionInfections and infestations1/232/233/46
Amylase increasedInvestigations2/230/232/46
Lipase increasedInvestigations2/230/232/46
HeadacheNervous system disorders1/232/233/46
CoughRespiratory, thoracic and mediastinal disorders2/231/233/46
HypertensionVascular disorders2/230/232/46

Baseline characteristics

Age, Continuous
Age, Continuous(Years)LTP001 6mgPlaceboTotal
Mean70.3 ± 7.0769.5 ± 5.3469.9 ± 6.21
Sex: Female, Male
Sex: Female, Male(Participants)LTP001 6mgPlaceboTotal
Female21113
Male211233
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LTP001 6mgPlaceboTotal
White232346
08

Study locations

15 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • University of Kansas Hospital
    Kansas City, Kansas 66160, United States
  • Novartis Investigative Site
    CABA, Buenos Aires C1056ABJ, Argentina
  • Novartis Investigative Site
    Ranelagh Partido de Berazate, Buenos Aires 1884, Argentina
  • Novartis Investigative Site
    Paraná, 3100, Argentina
  • Novartis Investigative Site
    Camperdown, New South Wales 2050, Australia
  • Novartis Investigative Site
    Chermside, Queensland 4032, Australia
  • Novartis Investigative Site
    Spearwood, Western Australia 6163, Australia
  • Novartis Investigative Site
    Prague, 140 59, Czechia
  • Novartis Investigative Site
    Munich, Bavaria 81377, Germany
  • Novartis Investigative Site
    Coswig, 01640, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Amsterdam, North Holland 1081 HV, Netherlands
  • Novartis Investigative Site
    Nieuwegein, Utrecht 3435 CM, Netherlands
  • Novartis Investigative Site
    Bialystok, 15-044, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Aug 2024, 21 months.

Results were first posted in Sep 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2022
First posted
Aug 11, 2022
StartActual
Nov 10, 2022
Primary completionActual
Aug 26, 2024
CompletionActual
Sep 26, 2024
Results first posted
Sep 18, 2025
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05497284
Responsible party
Sponsor
First posted
Aug 11, 2022
Start date
Nov 10, 2022
Primary completion
Aug 26, 2024
Completion
Sep 26, 2024
Results posted
Sep 18, 2025
Last update
Jan 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LTP001

Start the discussion